DEF: Harvard Bioscience Announces 2025 Annual Meeting of Stockholders, Proposes Amended Incentive Plan

Harvard Bioscience will hold its 2025 Annual Meeting of Stockholders virtually on June 2, 2025, to vote on director election, auditor ratification, executive compensation, and an amended incentive plan.

Summary

• Harvard Bioscience, Inc. will hold its 2025 Annual Meeting of Stockholders on June 2, 2025, as a virtual meeting.
• Stockholders will vote on the election of one Class I Director, the ratification of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, an advisory vote on executive compensation, and the approval of the Amended and Restated 2021 Incentive Plan.
• The Board of Directors recommends voting FOR all proposals.
• The record date for determining stockholders entitled to vote at the Annual Meeting is April 7, 2025.
• The company is proposing an amendment to its 2021 Incentive Plan to increase the number of authorized shares by 3,923,000.
• Bertrand Loy will not stand for re-election, decreasing the board size to four members.

Sentiment

Score: 7

Explanation: The document is neutral in tone, providing necessary information for the annual meeting and corporate governance matters. The company highlights its commitment to ethical and responsible business practices, which contributes to a positive outlook.

Positives

• The company is committed to enabling the discovery, safety and regulatory testing, and production of tomorrows therapeutics.
• The company strives to minimize its environmental impact through efficient energy and water usage, waste reduction, and recycling.
• The company fosters a culture that promotes fairness, respect, and opportunity for all employees.
• The company has established a Code of Business Conduct and Ethics and a confidential ethics hotline.

Negatives

• Mr. Bertrand Loy has informed the Company of his decision not to stand for re-election.
• Jennifer Cote has notified the Company of her resignation from the Company effective upon the filing the Company Quarterly Report on Form 10-Q for the period ended March 31, 2025.

Risks

• The company faces risks related to legal, compliance, and cybersecurity matters.
• The company's financial performance could be impacted by various factors, including those related to financial reporting and internal controls.
• The company's compensation programs could pose risks if not properly managed.
• The company's success depends on attracting and retaining key personnel.

Future Outlook

The Board of Directors intends to assess the size of the Board of Directors following the Annual Meeting.

Management Comments

• James W. Green, Chairman of the Board, President and Chief Executive Officer, cordially invites stockholders to attend the 2025 Annual Meeting.
• The Board of Directors recommends a vote FOR the election of the nominee of the Board of Directors as a Director of the Company; FOR the proposal to ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025; FOR the proposal to approve, by a non-binding advisory vote, of the compensation of our named executive officers; and FOR the approval of the Amended and Restated 2021 Incentive Plan.

Industry Context

Harvard Bioscience operates in the life science research and drug development tools industry, providing products and services to enable advances in these fields.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards.
• The document does list a peer group of companies used for compensation benchmarking including Champions Oncology, Inc., Pro-Dex, Inc., Electromed, Inc., Standard Biotools, Inc., Enzo Biochem, Inc., Suralign Holdings, Inc., IRIDEX Corporation, Surmodics, Inc., Le Maitre Vascular, Inc., T2 Biosystems, Inc., Meridian Bioscience, Inc., Transcat, Inc., OraSure Technologies, Inc., and UFP Technologies, Inc.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders are asked to vote on key proposals affecting the company's governance and executive compensation.
• Employees may be affected by changes to the incentive plan.
• Customers and suppliers may be indirectly affected by changes in the company's governance and strategic direction.

Next Steps

• Stockholders are encouraged to vote through the internet, by telephone, or by mail.
• The Board of Directors will assess the size of the Board of Directors following the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Harvard Bioscience, Stockholders, Director Election, Executive Compensation, Incentive Plan, Grant Thornton, Corporate Governance, Board of Directors